Loading provider…
Loading provider…
Clinical Genetics (M.D.) Physician in Wilmington, DE
NPI: 1255422531Primary Employer
Nemours Children's Health
nemours.org
HQ Phone
Get MD Michael's Phone Numberphone_androidMobile
Get MD Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardDE State Medical License
DE State Medical License
2005 - 2027
FL State Medical License
2017 - 2025
OH State Medical License
2014 - 2025
NY State Medical License
2020 - 2024
PA State Medical License
2005 - 2024
MD State Medical License
2001 - 2022
TX State Medical License
2003 - 2005
LA State Medical License
1997 - 2003

American Board of Pediatrics
Pediatrics

American Board of Medical Genetics and Genomics
Clinical Genetics and Genomics

American Board of Medical Genetics and Genomics
Clinical Molecular Genetics and Genomics
Johns Hopkins University
Residency • Medical Genetics and Genomics
1998 - 2001
Fellowship • Medical Genetics and Genomics
Until 2001
Tulane School of Medicine
medicine.tulane.edu
Medical School
Until 1996
Tulane University
Residency • Pediatrics
1996 - 1998
Majewski osteodysplastic primordial dwarfism type II (MOPD II): expanding the vascular phenotype.
Authors: Gary Steinberg, Jeffrey Feinstein
Journal: Am J Med Genet A
Growth in individuals with Saul-Wilson syndrome
Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.
Authors: Shunji Tomatsu, Kazuki Sawamoto, Carlos Alméciga Díaz, Tsutomu Shimada, Michael Bober, Yasutsugu Chinen, Hiromasa Yabe, Adriana Montaño, Roberto Giugliani, Francyne Kubaski, Eriko Yasuda, Alexander Rodríguez López, Angela Espejo Mojica, Oscar Sánchez, Robert Mason, Luis Barrera, William Mackenzie, Tadao Orii
Publication Date: 2015-04-22
Lead Sponsor: Ascendis Pharma A/S
Intervention / Treatment: DRUG: TransCon CNP, DRUG: Placebo for TransCon CNP
Lead Sponsor: QED Therapeutics, Inc., a Bridgebio company
Intervention / Treatment: DRUG: Infigratinib 0.016 mg/kg, DRUG: Infigratinib 0.032 mg/kg, DRUG: Infigratinib 0.064 mg/kg, DRUG: Infigratinib 0.128 mg/kg, DRUG: Infigratinib 0.25 mg/kg
Lead Sponsor: QED Therapeutics, Inc., a Bridgebio company